Literature DB >> 12834190

Safety of intra-articular hyaluronates for pain associated with osteoarthritis of the knee.

J F Rick Hammesfahr1, Alan B Knopf, Todd Stitik.   

Abstract

Sodium hyaluronate (Hyalgan, and Supartz) and hylan G-F 20 (Synvisc) are hyaluronans (HA) injected intra-articularly for pain relief in osteoarthritis of the knee. Each product has demonstrated a very favorable safety profile in clinical trials and practice. The most common adverse event associated with their use is mild injection site pain and swelling. Rare incidences of pseudogout and anaphylactoid reactions have been reported to be associated with their use. Occasionally, pseudosepsis, also known as a severe acute inflammatory reaction (SAIR) syndrome, has been reported to be associated with these products. Clinical and postmarketing data indicate that HA therapy is a safe treatment for osteoarthritis of the knee.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12834190

Source DB:  PubMed          Journal:  Am J Orthop (Belle Mead NJ)        ISSN: 1078-4519


  15 in total

Review 1.  Calcium Pyrophosphate Deposition Disease.

Authors:  Ann K Rosenthal; Lawrence M Ryan
Journal:  N Engl J Med       Date:  2016-06-30       Impact factor: 91.245

Review 2.  Adverse events from diagnostic and therapeutic joint injections: a literature review.

Authors:  Cynthia Peterson; Juerg Hodler
Journal:  Skeletal Radiol       Date:  2009-12-01       Impact factor: 2.199

3.  Choice of intra-articular injection in treatment of knee osteoarthritis: platelet-rich plasma, hyaluronic acid or ozone options.

Authors:  Tahir Mutlu Duymus; Serhat Mutlu; Bahar Dernek; Baran Komur; Suavi Aydogmus; Fatma Nur Kesiktas
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2016-04-07       Impact factor: 4.342

Review 4.  Current Concepts and Future Directions of Minimally Invasive Treatment for Knee Pain.

Authors:  Daryl T Goldman; Rachel Piechowiak; Daniel Nissman; Sandeep Bagla; Ari Isaacson
Journal:  Curr Rheumatol Rep       Date:  2018-07-23       Impact factor: 4.592

Review 5.  State-of-the-Art management of knee osteoarthritis.

Authors:  Kenton H Fibel; Howard J Hillstrom; Brian C Halpern
Journal:  World J Clin Cases       Date:  2015-02-16       Impact factor: 1.337

6.  The effects of carboxymethylated chitosan on metalloproteinase-1, -3 and tissue inhibitor of metalloproteinase-1 gene expression in cartilage of experimental osteoarthritis.

Authors:  Shi-Qing Liu; Bo Qiu; Ling-Yun Chen; Hao Peng; Yu-Min Du
Journal:  Rheumatol Int       Date:  2005-03-12       Impact factor: 2.631

Review 7.  Hyaluronic acid (Supartz®): a review of its use in osteoarthritis of the knee.

Authors:  Monique P Curran
Journal:  Drugs Aging       Date:  2010-11-01       Impact factor: 3.923

Review 8.  Viscosupplementation for the treatment of osteoarthritis of the knee.

Authors:  N Bellamy; J Campbell; V Robinson; T Gee; R Bourne; G Wells
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

Review 9.  Status of hyaluronan supplementation therapy in osteoarthritis.

Authors:  Roy D Altman
Journal:  Curr Rheumatol Rep       Date:  2003-02       Impact factor: 4.686

10.  Managing joint pain in osteoarthritis: safety and efficacy of hylan G-F 20.

Authors:  Augustine H Conduah; Champ L Baker; Champ L Baker
Journal:  J Pain Res       Date:  2009-07-06       Impact factor: 3.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.